ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
RANCHO CORDOVA, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp.
(Nasdaq:KOOL), a leading supplier of enabling technologies for the processing
and storage of cell therapies, today said it will be participating in the
25^th Annual Roth Conference on Wednesday, March 20.
The presentation by Matthew T. Plavan, Chief Executive Officer, will begin at
8:30 a.m., Pacific Daylight Time (11:30 a.m., Eastern Daylight Time).
The presentation will be available through the conference website at
http://wsw.com/webcast/roth27/kool/ and via the Company's website at
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and
manufacturing automated blood processing systems and disposable products that
enable the separation, preservation and delivery of cell and tissue therapy
products. These include:
*The BioArchive^® System, an automated cryogenic device, used by cord blood
stem cell banks in more than 30 countries for cryopreserving and archiving
cord blood stem cell units for transplant.
*AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
devices that includes the AXP and the MXP^® MarrowXpress^® and companion
sterile blood processing disposables for harvesting stem cells in closed
systems. The AXP device is used for the processing of cord blood. The MXP
is used for the preparation of cell concentrates, including stem cells
from bone marrow aspirates in the laboratory setting.
*The Res-Q^® 60 BMC/PRP (Res-Q), a point-of-care system designed for the
preparation of cell concentrates, including stem cells, from bone marrow
aspirates and whole blood for platelet rich plasma (PRP).
The ThermoGenesis Corp. logo is available at
This press release contains forward-looking statements.These statements
involve risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements. Several
factors including timing of FDA and foreign regulatory approvals, changes in
customer forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets for
customers' products, introduction timing and acceptance of our new products
scheduled for fiscal year 2013, and introduction of competitive products and
other factors beyond our control could result in a materially different
revenue outcome and/or in our failure to achieve the revenue levels we expect
for fiscal 2013.A more complete description of these and other risks that
could cause actual events to differ from the outcomes predicted by our
forward-looking statements is set forth under the caption "Risk Factors" in
our annual report on Form 10-K and other reports we file with the Securities
and Exchange Commission from time to time, and you should consider each of
those factors when evaluating the forward-looking statements.
CONTACT: ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
ThermoGenesis Corp. Logo
Press spacebar to pause and continue. Press esc to stop.